Premium
β‐Cell signalling and insulin secretagogues: A path for improved diabetes therapy
Author(s) -
Seino Susumu,
Sugawara Kenji,
Yokoi Norihide,
Takahashi Harumi
Publication year - 2017
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12995
Subject(s) - incretin , insulin , glucokinase , diabetes mellitus , endocrinology , medicine , type 2 diabetes , receptor , insulin receptor , glucagon like peptide 1 , glucagon like peptide 1 receptor , dipeptidyl peptidase 4 , beta cell , chemistry , pharmacology , agonist , insulin resistance , islet
Insulin secretagogues including sulfonylureas, glinides and incretin‐related drugs such as dipeptidyl peptidase 4 (DPP‐4) inhibitors and glucagon‐like peptide‐1 receptor agonists are widely used for treatment of type 2 diabetes. In addition, glucokinase activators and G‐protein‐coupled receptor 40 (GPR40) agonists also have been developed, although the drugs are not clinically usable. These different drugs exert their effects on insulin secretion by different mechanisms. Recent advances in β‐cell signalling studies have not only deepened our understanding of insulin secretion but also revealed novel mechanisms of insulin secretagogues. Clarification of the signalling mechanisms of the insulin secretagogues will contribute to improved drug therapy for diabetes.